Intrahepatic Cholestasis of Pregnancy (ICP) Cell Models for Research

Intrahepatic cholestasis of pregnancy (ICP) is the most common pregnancy-specific liver disorder, characterized by pruritus and elevated serum bile acids, typically presenting in the second or third trimester. Global incidence varies widely, with the highest rates in South America (especially Chile, up to 15% historically) and lower rates in Europe and North America (0.1–2%). According to WHO, ICP is a significant cause of maternal morbidity and is associated with increased risk of preterm birth, fetal distress, and stillbirth. Key risk factors include genetic predisposition (variants in ABCB4, ABCB11, ATP8B1, NR1H4), elevated estrogen levels, and multiple gestations. The condition resolves postpartum but recurs in 40–70% of subsequent pregnancies. While maternal mortality is rare, fetal complications drive clinical urgency. Five-year survival is not applicable as ICP is not a malignant disease; however, fetal mortality rates without treatment can reach 1–2% in severe cases. Research into ICP is critical to understand bile acid homeostasis and develop targeted therapies.

ICP serves as an excellent model for studying bile acid transport, cholestasis mechanisms, and pregnancy-related hormonal regulation. The disease has a strong genetic component, with well-characterized variants in hepatobiliary transporters, making it ideal for gene-editing studies. Public datasets such as ClinVar and NCBI Gene provide variant information, while GEO hosts transcriptomic data from ICP patients. Open questions include: How do heterozygous mutations in ABCB4 and ABCB11 interact with hormonal factors? What are the molecular drivers of pruritus? And how can we predict which pregnancies will be complicated by ICP? Gene-edited cell models allow precise interrogation of these questions.

ICP is not a carcinogenic process, but its pathogenesis involves key hepatobiliary pathways:

1. Bile acid transport and cholestasis:

• • Mutations in ABCB4 (MDR3) impair phosphatidylcholine secretion, leading to bile duct damage.
• • ABCB11 (BSEP) mutations reduce bile salt export, causing intracellular bile acid accumulation.
• • ATP8B1 (FIC1) mutations disrupt aminophospholipid flippase activity, affecting membrane integrity.

2. Hormonal regulation:

• • Estrogen and progesterone metabolites (e.g., estradiol-17β-glucuronide) inhibit BSEP and MRP2, exacerbating cholestasis.
• • Progesterone sulfate inhibits FXR, reducing bile acid synthesis feedback.

3. Nuclear receptor signaling:

• • FXR (NR1H4) regulates bile acid homeostasis; its dysfunction leads to elevated bile acids.
• • PXR (NR1I2) and VDR (VDR) modulate detoxification pathways.

4. Inflammatory and immune responses:

• • Bile acid accumulation triggers inflammasome activation and release of pro-inflammatory cytokines (IL-6, TNF-α).
• • Immune-mediated bile duct injury may contribute to disease severity.

Data from ClinVar and COSMIC (for somatic mutations in liver cancer, not ICP). Frequencies are approximate and vary by population.

• • FXR/RXR pathway:
• • NR1H4 (FXR) downregulation reduces SHP (NR0B2) expression, increasing CYP7A1 and bile acid synthesis.
• • RXRα (RXRA) partners with FXR; its dysfunction impairs heterodimer formation.
• • MAPK/ERK pathway:
• • Bile acids activate EGFR and MAPK, promoting cholangiocyte proliferation and inflammation.
• • ERK1/2 phosphorylation is elevated in ICP models.
• • PI3K/AKT/mTOR pathway:
• • Bile acid-induced AKT activation protects hepatocytes from apoptosis but may promote fibrosis.
• • mTOR inhibition reduces bile duct proliferation in preclinical models.
• • NF-κB pathway:
• • Bile acids activate NF-κB, driving pro-inflammatory cytokine expression (TNF-α, IL-6).
• • This contributes to pruritus and liver injury.
• • JAK/STAT pathway:
• • IL-6 activates STAT3, which regulates bile acid transporters and acute phase response.
• • STAT3 inhibition reduces cholestatic injury in animal models.

Organoids derived from ICP patients offer a physiologically relevant model with native genetic background. They can be gene-edited to create isogenic controls, enabling precise genotype-phenotype studies.

• • Mdr2 (Abcb4) knockout mice: Develop cholestasis and liver injury; model PFIC3 and ICP-like features.
• • Bsep (Abcb11) knockout mice: Show severe cholestasis; useful for studying bile acid toxicity.
• • Fxr (Nr1h4) knockout mice: Impaired bile acid feedback; elevated serum bile acids.
• • Estrogen-induced cholestasis models: Rodents treated with ethinylestradiol develop reversible cholestasis.
• • PDX models: Not applicable for ICP as it is not a cancer; however, patient-derived xenografts of liver tissue can be used for drug testing.
• • Induced pluripotent stem cell (iPSC)-derived hepatocytes: Can be differentiated from ICP patients and gene-edited for mechanistic studies.

CRISPR-Cas9 technology enables the creation of isogenic cell lines with precise genetic alterations. For ICP, key models include:

• • ABCB4 knockout HepG2: Lacks MDR3 function, leading to impaired phosphatidylcholine secretion and bile canaliculi damage.
• • ABCB11 knockout HepaRG: Deficient BSEP activity, resulting in intracellular bile acid accumulation.
• • ATP8B1 knockout Huh-7: Disrupted FIC1 function, affecting membrane lipid asymmetry.
• • NR1H4 knockout HepG2: Loss of FXR, causing upregulated CYP7A1 and increased bile acid synthesis.
• • ABCB4 knock-in (e.g., c.504C>T): Introduces common ICP variant for studying dominant-negative effects.
• • ABCB11 knock-in (e.g., p.E297G): Models severe ICP and PFIC2.
• • Reporter lines: BSEP (ABCB11) promoter-driven luciferase or fluorescent reporters for high-throughput screening.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing reproducible, validated tools. These models are generated using CRISPR and are quality-controlled for off-target effects and genomic integrity. They enable researchers to study bile acid transport, drug responses, and genotype-specific phenotypes without the variability of patient samples.

Knockout and knock-in lines validate gene function in bile acid homeostasis. For example:

• • ABCB4 knockout HepG2 cells show reduced phosphatidylcholine in bile canaliculi, confirming MDR3's role.
• • ABCB11 knockout HepaRG cells accumulate bile acids, demonstrating BSEP's necessity for bile flow.
• • NR1H4 knockout cells exhibit increased CYP7A1 expression, validating FXR's feedback regulation.
• • ATP8B1 knockout Huh-7 cells display altered membrane lipid composition, linking FIC1 to cholestasis.

These models allow researchers to test hypotheses about variant pathogenicity and gene-environment interactions (e.g., estrogen effects).

Isogenic pairs (wild-type vs. mutant) are powerful for drug screening:

• • Ursodeoxycholic acid (UDCA) is the standard treatment; gene-edited cells help identify responders vs. non-responders based on genotype.
• • Novel FXR agonists (e.g., obeticholic acid) can be tested for efficacy in NR1H4 knockout vs. wild-type cells.
• • BSEP inhibitors (e.g., cyclosporine) can be evaluated for cholestatic potential using ABCB11 knockout models.
• • Resistance modeling: Cells with ABCB4 mutations may resist UDCA's protective effects, guiding combination therapies.
• • High-throughput screens using BSEP reporter lines can identify compounds that modulate bile acid transport.

CRISPR synthetic lethality screens identify genes that are essential only in the context of specific mutations. For ICP:

• • Genome-wide knockout screens in ABCB4-mutant cells can reveal synthetic lethal partners (e.g., genes in the phosphatidylcholine synthesis pathway).
• • ABCB11-mutant cells can be screened for vulnerabilities to bile acid-induced toxicity, identifying protective genes.
• • Biomarker candidates: Serum bile acid levels, microRNAs (e.g., miR-21), and bile acid metabolites are being explored. Gene-edited cells help validate these biomarkers by linking genotype to biomarker expression.
• • Pharmacogenomic markers: Variants in ABCB4/ABCB11 predict response to UDCA; gene-edited cells can confirm these associations.